On : 15 july 2025
• The global Sevelamer Carbonate API market was valued at USD 403 million in 2024. The market is projected to grow from USD 421 million in 2025 to USD 538 million by 2032, exhibiting a CAGR of 4.3% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Sevelamer Carbonate API is the active pharmaceutical ingredient used in medications for treating hyperphosphatemia in chronic kidney disease patients. As a phosphate binder, it works by preventing phosphate absorption in the gastrointestinal tract, thereby managing elevated serum phosphate levels that can lead to serious complications. The API undergoes stringent quality control processes to ensure purity and efficacy in final drug formulations.
Email: help@intelmarketresearch.com +91 9169164321
•Sevelamer Carbonate API Powder
•Sevelamer Carbonate API Granules
•Sevelamer Carbonate API Pellets
Large Pharmaceutical Companies
Generic Drug Manufacturers
Contract Manufacturing Organizations
•Aurobindo Pharma (India)
•Sun Pharmaceutical Industries Ltd. (India)
•EUROAPI (France)
•Hetero Drugs Limited (India)
•Emcure Pharmaceuticals Ltd. (India)
•Solara Active Pharma Sciences (India)
•Formosa Laboratories, Inc. (Taiwan)
•Guangzhou Tosun Pharmaceutical Co., Ltd. (China)
Email: help@intelmarketresearch.com +91 9169164321
